34 studies found for:    " August 13, 2008":" September 12, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Terminated TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.
Condition: HIV-1
Intervention: Drug: TMC278
22 Terminated
Has Results
Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
Conditions: HIV;   Hepatitis C;   Liver Disease;   Fatty Liver;   Steatosis
Intervention: Drug: Pioglitazone
23 Completed TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.
Conditions: HIV;   AIDS;   Hepatic Impairment
Intervention: Drug: TMC278
24 Terminated
Has Results
A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)
Condition: HIV
Interventions: Drug: Comparator: Raltegravir 400 mg b.i.d.;   Drug: Experimental: Raltegravir 800 mg q.d.;   Drug: TRUVADA™
25 Terminated A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
Conditions: HIV;   Tuberculosis
Interventions: Drug: lopinavir/ritonavir;   Drug: rifabutin
26 Active, not recruiting Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
Conditions: HIV;   Hepatitis C;   Infections
Intervention: Drug: Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)
27 Completed TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.
Conditions: HIV;   AIDS;   Oral Contraceptive
Intervention: Drug: TMC278
28 Completed Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
Condition: HIV
Intervention: Drug: Raltegravir
29 Completed TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.
Condition: HIV
Intervention: Drug: TMC278
30 Completed
Has Results
A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen
Conditions: Virus Diseases;   HIV
Intervention: Drug: Switch NRTIs as a Backbone to Raltegravir in HIV-Infected Patients from a Stable Boosted PI Regimen
31 Completed TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.
Conditions: HIV;   AIDS
Intervention: Drug: Darunavir
32 Terminated Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML)
Condition: Progressive Multifocal Leukoencephalopathy
Intervention: Drug: mefloquine
33 Completed Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
Conditions: Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: educational intervention
34 Completed Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
Conditions: Lung Cancer;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: bevacizumab;   Drug: vandetanib;   Other: laboratory biomarker analysis;   Other: pharmacological study

Show previous page of results Previous Page (1-20) Studies Shown (21-34) Next Page
Indicates status has not been verified in more than two years